Equilibrium dialysis and Sephadex gel filtration methods were used to study the binding of chlorophenoxyisobutyric acid (CPIB), tibric (TA) and nicotinic (NA) acids as well as CPIB ethyl ester (clofibrate) and TA and NA isopropyl esters (TAPE and NAPE) to human lipoproteins of low density (LDL, ILDL and VLDL) and high density (HDL).
Binding to Plasma Lipoproteins of Chlorophenoxyisobutyric, Tibric and Nicotinic Acids and their Esters [Abstract] by Professor J L Beaumont and Mme C Dachet (Hopital Henri Mondor, Creteil, France) Equilibrium dialysis and Sephadex gel filtration methods were used to study the binding of chlorophenoxyisobutyric acid (CPIB), tibric (TA) and nicotinic (NA) acids as well as CPIB ethyl ester (clofibrate) and TA and NA isopropyl esters (TAPE and NAPE) to human lipoproteins of low density (LDL, ILDL and VLDL) and high density (HDL) .
It was found that clofibrate and TAPE bind strongly to lipoproteins and that their acids, CPIB and TA and also NA and NAPE, do not bind. In the same experimental conditions it was found that clofibrate and TAPE bound only weakly to human seruni albumin (HSA) and that CPIB bound to HSA with an equilibrium constant (Ka) of 3.3 x 105M for one site of high affinity.
The clofibrate and TAPE bound to lipoproteins do not dissociate either by dialysis or by filtration of Sephadex G 25. The binding percentage remains constant for all drug concentrations studied, and the molar ratio of bound drug increases linearly with increasing concentrations. This suggests that the interaction may be irreversible, and there is some evidence that binding may -~~~~~~~~~~~~. ... ....O. By comparing these results with those already found in experiments with three other related clofibrate drugs, it is proposed that in their interaction with lipoproteins, the phenyl groups are necessary and the esterification is contributory. The possible role of this interaction in the lipid lowering effect of the drugs is discussed, with special reference to their possible implication in lipoprotein synthesis within intestinal and hepatic cells.
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DISCUSSION
Dr H R Arntz (Berlin) noted that in Dr Olsson's data there seemed to be a difference in the timing of the drug's maximum effects on VLDL and LDL lipids.
Dr Olsson agreed that the maximum decrease in VLDL triglycerides appeared after four weeks, butforLDL triglycerides it occurred after 12 weeks. He had no explanation for this effect. The same applied to VLDL levels and LDL cholesterol levels. In answer to Dr Arntz's further question, he had not performed lipoprotein analyses between four and 12 weeks, but had to rely on total levels. Professor E A Nikkila (Chairman) asked if there was any correlation between the decrease of VLDL and LDL in individual cases. Dr Olsson said that there appeared to be some negative relationship between VLDL and LDL, but it was hard to draw conclusions from individual observations.
Dr Arntz asked whether there were patients with tendon xanthomas in the group. Tendon xanthomas in type Ila patients might cause a delay in the decrease of LDL if the xanthoma itself was a source of cholesterol. Dr Olsson doubted if this effect would be significant.
Dr V Rahlfs (Munich) commented on the correlations which Dr Olsson had used and pointed out that plotting the initial values against difference values led to nonsense correlations and thus could be avoided. The fallacy of this procedure was amply demonstrated in the work of P D Oldham (1968, Measurement in Medicine, The Interpretation of Numerical Data. English Universities Press, London). However, initial values might be plotted against final (raw) values.
Dr Olsson agreed that to do so might give additional information.
Professor B Lewis (London) doubted whether the total lipid reduction (both cholesterol and total triglyceride) by gemfibrozil could be accounted for entirely on the basis of changes in the concentration of normal lipoproteins. There seemed also to be a change in the composition of both LDL and HDL with decreased triglyceride-cholesterol ratios. This might suggest a primary effect on, for example, triglyceride metabolism, leading to secondary effects in all three density classes. If so, this would differ, for example, from the effect of cholestyramine which seemed to alter the concentration of normal lipoproteins. Some patients responded well to this drug and others occasionally showed no response, though not through lack of compliance. Davignon in Canada suggested that those patients with hyperbetalipoproteinemia who responded well to clofibrate were the ones in whom the total cholesterol to total triglyceride ratio in serum was very high, at the upper end of the frequency distribution. Those patients, in other words, with high cholesterol and relatively low triglycerides seemed to do better. He asked whether Dr Olsson could predict, from any initial analyses, which patients would respond best to gemfibrozil.
Dr Olsson said that such predictions could not be made at present. However, the decreases in composition were very interesting. There were very clear decreases in HDL triglyceride and an increase in HDL cholesterol, at least in type IV patients. The acute effect on VLDL and the slower effect on LDL triglycerides may in the future throw more light on the mechanisms of lipoprotein metabolism.
Dr Vessby said that similar effects were observed in clofibrate treatment. A similar reduction in relative quantities of triglycerides in LDL and HDL occurred if they were initially high. This might be regarded as a normalization of lipo-protein composition. This closer approach to the relations seen between cholesterol and triglycerides in the normal population was also seen with other drugs and was not unique to gemfibrozil treatment.
Dr R M Hodges (Ann Arbor) commented that in Dr Virtamo's study there had been a number of failures with both drugs. He asked if Dr Virtamo intended to carry out a cross-over study putting those patients who had failed on gemfibrozil onto clofibrate and vice versa, and Dr Virtamo agreed that this was his intention.
Dr A H Kissebah (London) asked whether the enhanced reduction of cholesterol in LDL in Dr Olsson's patients represented a change from type II to type IV during the treatment, or whether it was a change in the triglyceride to cholesterol ratio in type III. In addition, he suggested that the insulin values in the hypertriglyceride patients described by Dr Vessby were remarkably low.
Dr Olsson said that the increased VLDL cholesterol in relation to triglyceride, the effect of cholesterol on VLDL in type III, and the pronounced effect of LDL triglycerides in all types, suggested that gemfibrozil had a particular action on the intermediary lipoproteins. The dramatic fall in VLDL cholesterol led to normalization and there were no signs of intermediary lipoproteins after treatment.
Dr Kissebah suggested that with a cut-off point of 1.006, intermediates would be expected to fall with LDL and one would expect a low cholesterol level in the type III patient. Dr Olsson, however, said that a high ratio of cholesterol to triglycerides in VLDL in type III indicated that intermediate lipoproteins were also being found at d< 1.006.
Dr Vessby said that the definition of type III is based on a demonstration of intermediary lipoproteins in VLDL. By performing the cut-off at 1.006 intermediate particles were found in both VLDL and LDL. The choice of 1.006 cuts through this intermediate particle distribution. Intermediate particles occur in the VLDL of type III and in the LDL as a result. Tnis may be the reason for the marked effect on VLDL and also for the decrease in LDL triglyceride concentration. In patients with high VLDL and low LDL concentrations before treatment, an increase of LDL reciprocal to a decrease in VLDL levels might be seen during treatment with diet or lipid lowering drugs. In the expressed type Ills, however, this paradoxical increase in LDL during Dr R A Okerholm (Ann Arbor) said that they had studied the binding of gemfibrozil to human serum albumin (HSA). The dissociation constant of the gemfibrozil-HSA complex was 1.5 x 1O-5 with one binding site, and gemfibrozil was 97% bound over the concentration range tested, in good agreement with Professor Beaumont's data on clofibrate.
Dr Olsson asked Professor Beaumont how he' correlated the effects of the drug with its binding properties.
Professor Beaumont believed that the effect must take place in the cells, whether in intestinal cells, hepatic or other cells. Most workers had now rejected the notion of a correlation between the hypolipideemic effect of clofibrate and its binding with serum albumin. There were too many discrepancies with different clofibrate-related drugs to accept this view. Now, by positing an interaction with lipoprotein within cells, rather than the circulating blood, many phenomena might be explained. It was shown by Berkovitz 15 years previously (1963, Journal of Atherosclerosis Research 3, 538) that post-absorptive lipwmia was lower following clofibrate. The turnover and production of VLDL was also lower during clofibrate treatment and might be similar with gemfibrozil. There was an accumulation of triglycerides, particularly in hepatic cells, as if it were not possible to transfer these triglycerides to other cells or to plasma lipoproteins. He believed that an interference with the transport protein at the site of synthesis would explain these phenomena, at least in part. In reply to the Chairman, he agreed that so far this hypothesis lacked evidence.
Professor Nikkilai suggested that the binding of clofibrate to lipoproteins might be a solubility phenomenon.
Professor Beaumont said that originally everyone accepted that such drugs acted chiefly on triglyceride levels. Later came the recognition of their action on both triglyceride and cholesterol. The link between these two metabolic pathways was found in the transport protein. There was a link between cholesterol esters and triglycerides in the structure of low density lipoproteins, and he believed this link was important in explaining the mode of action. treatment did not occur. The failure of low LDL levels to rise after treatment might be beneficial to the patient.
The low insulin levels might have been due to the fact that there were not many patients in the group who were glucose intolerant, nor were there many obese individuals. In his view, high insulin levels were seen more frequently in type IVs who were overweight and who had glucose intolerance.
Dr Kissebah did not agree. He believed that the high incidence in the type IVs was present despite these two factors. They usually have normal or very mild glucose intolerance. Nonetheless, he thought that Dr Vessby's insulin figures were very low for this type of patient.
Professor K Irsigler (Vienna) asked if any investigator had calculated the protein portion of the lipoprotein and thus been able to assess whether there was a reduction in the formation of this lipoprotein or only a qualitative change in its composition.
Dr Vessby had not measured the protein content. Dr Olsson had not measured it either, but speculated that there would probably be a decrease in protein content.
Dr Kissebah had measured total protein and certain protein fractions in some patients treated with the drug and did not find any change in the ratio of protein composition. There was definitely an increase in the LDL apo-B-protein, but this increase was still within the normal range because such patients started at lower levels. In answer to Dr Vessby's question he said that all patients were type IV.
Dr P Ghosh (Cambridge) questioned Dr Vessby's glucose tolerance data. He said that type III and type IV patients, irrespective of whether they were overweight or not, were likely to have high insulin concentrations following either oral or intravenous glucose load or the tolbutamide test. Dr Vessby said that his figures were derived from a total group of 30 patients, of whom only a minority were type IVs and different kinds of type IVs. He did not expect mean values to be very high in such a group. If type IV patients only were studied, higher mean values would be expected.
